Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Cantargia AB ( (SE:CANTA) ) has shared an update.
Cantargia AB has published preclinical data in Cancer Discovery demonstrating that targeting IL1RAP with nadunolimab can effectively counteract tumor-induced systemic immune suppression by blocking immune suppressive myeloid cells. The findings, supported by clinical data, highlight nadunolimab’s potential to enhance cancer treatment by reducing immunosuppressive neutrophils and improving the efficacy of cancer vaccines. These results suggest significant implications for improving immunotherapy outcomes, particularly in cancers like pancreatic and non-small cell lung cancer.
More about Cantargia AB
Cantargia AB is a biotechnology company focused on developing antibody-based treatments for life-threatening diseases. The company has established a platform centered on the protein IL1RAP, which is involved in various cancer forms and inflammatory diseases. Cantargia’s oncology program features the antibody nadunolimab, primarily studied in combination with chemotherapy for pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer. Additionally, Cantargia is working on another antibody, CAN10, targeting autoimmune and inflammatory diseases.
YTD Price Performance: -2.61%
Average Trading Volume: 2,500
Technical Sentiment Signal: Buy
Current Market Cap: €36.77M
Find detailed analytics on CANTA stock on TipRanks’ Stock Analysis page.